Ex vivo engineering of phagocytic signals in breast cancer cells for a whole tumor cell-based vaccine
These results suggest that tumor cells obtained from surgical samples of a breast cancer patient could be engineered ex vivo and used as a novel cell therapy to drive antitumor immunity.
Authors
- Román Martí-Díaz (ORCID: https://orcid.org/0000-0001-5792-7665)
- María F. Montenegro (ORCID: https://orcid.org/0000-0002-0064-0484)
- Trinidad Hernández‐Caselles (ORCID: https://orcid.org/0000-0001-6727-8320)
- Luís Sánchez‐del‐Campo (ORCID: https://orcid.org/0000-0002-9537-7761)
- Juan Cabezas‐Herrera (ORCID: https://orcid.org/0000-0001-9053-5380)
- José Neptuno Rodrı́guez-López (ORCID: https://orcid.org/0000-0001-6863-1173)
- Antonio Piñero (ORCID: https://orcid.org/0000-0002-7718-8318)
Institutions
- Instituto Murciano de Investigación Biosanitaria (ES)
- Hospital Universitario Virgen de la Arrixaca (ES)
- Universidad de Murcia (ES)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12885-025-14432-1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundación Séneca
- Ministerio de Ciencia, Innovación y Universidades
- Agencia Estatal de Investigación
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz